CD274 and neoplasm: In 2019, atezolizumab was approved in combination with nab-paclitaxel as a treatment option for PD-L1–positive (PD-L1–stained, tumor-infiltrating immune cells of any intensity covering ≥1% of the tumor area) metastatic TNBC; however, a follow-up study of atezolizumab plus paclitaxel failed to meet its primary endpoint of progression-free survival (PFS) for first-line treatment of patients with PD-L1–positive metastatic TNBC (14–16).